A Phase 4 interventional study of Valproic acid, sodium salt in Bipolar Disorder, sponsored by Sanofi. Completed at 1 site in Turkey. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2009-05-29.
Sponsored by Sanofi · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies testing Valproic Acid in Bipolar Disorder — none open to participants now, none under way, none of them phase 3. Valproic Acid · Bipolar Disorder.
Among the 41 studies testing Valproic Acid in Bipolar Disorder, this one is the 21st largest by enrollment, is one of 11 that started in 2004, is one of 20 in phase 4, and was the 26th registered.
1,685 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.
Browse Bipolar Disorder studies →None of the 41 studies testing Valproic Acid in Bipolar Disorder is open now. The open studies under Bipolar Disorder, anywhere →
Valproic Acid: first FDA approval 1978 (DEPAKENE). What it is approved for, and how studies give it, is on its page →
Of the 208 Bipolar Disorder studies recruiting now, 59 (28%) set no upper age limit and 136 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 4 · Phase 3 11 · Phase 4 20
First in 1997; this study’s year is marked. 11 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 58 is close to the median of 64 across 1,280 interventional studies indexed under Bipolar Disorder.
Median enrollment 58 across the 41 interventional studies. Of the 36 that completed or were terminated, 14 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 41 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
Sanofi has 5 studies filed under Bipolar Disorder — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 41 studies testing Valproic Acid in Bipolar Disorder, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
To assess regional N-acetyl aspartate (NAA) levels in drug free bipolar patients either in manic/hypomanic, or depressive or euthymic state
Time frame: for 6 weeks
To investigate valporate's effect on total and regional gray matter volume and NAA levels;
Time frame: for 6 weeks
To assess evoked and event related potentials to visual and auditory stimuli in patients before and after valproate monotherapy in comparison to healthy controls
Time frame: for 6 weeks
To determine the relationship between clinical improvement and image data changes in depressed or manic/hypomanic patients,
Time frame: for 6 weeks
The record gives a start of Dec 2004, a primary completion of Oct 2006 and a completion of Oct 2006. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Valproic Acid